Planchard D - Search Results

1

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup. Scherpereel A, et al. Among authors: planchard d. Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16. Lancet Oncol. 2019. PMID: 30660609 Clinical Trial.

2

Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II study.

Planchard D, Bourgeois H, Adoun M, Paitel JF, Blanc P, Genet D, Ferru A, Meurice JC, Deletage C, Tourani JM. Planchard D, et al. Am J Clin Oncol. 2006 Aug;29(4):345-51. doi: 10.1097/01.coc.0000221320.81753.a9. Am J Clin Oncol. 2006. PMID: 16891860 Clinical Trial.

3

The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma.

Planchard D, Domont J, Taranchon E, Monnet I, Tredaniel J, Caliandro R, Validire P, Besse B, Soria JC, Fouret P. Planchard D, et al. Ann Oncol. 2009 Jul;20(7):1257-63. doi: 10.1093/annonc/mdn785. Epub 2009 Mar 17. Ann Oncol. 2009. PMID: 19297315 Free article.

4

Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors.

Barlési F, Balleyguier C, Besse B, Bonodeau F, Brenac F, Corneloup O, Dansin E, Ferretti G, Gaubert JY, Gervais R, Lacombe C, Loundou A, Moro-Sibilot D, Planchard D, Scherpereel A, Menu Y. Barlési F, et al. Among authors: planchard d. Ann Oncol. 2010 Aug;21(8):1682-1686. doi: 10.1093/annonc/mdp590. Epub 2010 Jan 11. Ann Oncol. 2010. PMID: 20064831 Free article.

5

[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].

Margery J, Rivière F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffié P. Margery J, et al. Among authors: planchard d. Rev Pneumol Clin. 2010 Sep;66(4):255-9. doi: 10.1016/j.pneumo.2010.07.013. Epub 2010 Sep 15. Rev Pneumol Clin. 2010. PMID: 20933167 French.

6

Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.

Abedallaa N, Tremblay L, Baey C, Fabre D, Planchard D, Pignon JP, Guigay J, Pechoux CL, Soria JC, de Montpreville VT, Besse B. Abedallaa N, et al. Among authors: planchard d. J Thorac Oncol. 2012 Jul;7(7):1179-83. doi: 10.1097/JTO.0b013e3182572ead. J Thorac Oncol. 2012. PMID: 22617247 Free article.

7

Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.

Raphael J, Le Teuff G, Hollebecque A, Massard C, Bahleda R, Margery J, Besse B, Soria JC, Planchard D. Raphael J, et al. Among authors: planchard d. Lung Cancer. 2014 Aug;85(2):251-7. doi: 10.1016/j.lungcan.2014.05.006. Epub 2014 May 14. Lung Cancer. 2014. PMID: 24882384 Clinical Trial.

8

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

Audigier-Valette C, Girard N, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlesi F. Audigier-Valette C, et al. Among authors: planchard d. Bull Cancer. 2014 Sep;101(9):823-31. doi: 10.1684/bdc.2014.1976. Bull Cancer. 2014. PMID: 25299566 French.

9

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Girard N, Audigier-Valette C, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlési F. Girard N, et al. Among authors: planchard d. Expert Rev Anticancer Ther. 2015 Feb;15(2):225-33. doi: 10.1586/14737140.2014.986103. Epub 2014 Nov 21. Expert Rev Anticancer Ther. 2015. PMID: 25413260 Review.

10

Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.

Raphael J, Massard C, Gong IY, Farace F, Margery J, Billiot F, Hollebecque A, Besse B, Soria JC, Planchard D. Raphael J, et al. Among authors: planchard d. Cancer Biomark. 2015;15(2):151-6. doi: 10.3233/CBM-140448. Cancer Biomark. 2015. PMID: 25519011

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

277 results

Search Page

Filters